To this end, it was reported that the triple-negative breast cancer (TNBC) cell lines with higher expression level of MYCN are more sensitive to BET inhibitor [12] and in prostate cancer cells, elevated BRD4 protein level confers resistance to JQ1 [13]. This evidence concerns the gene MYCN and prostate cancer.